travel and meeting programs from the onset of the new company set-up. At the same time, GSK focused on return to travel in 2022, with $32.4 million in U.S.-booked air volume, compared with just $3.5 ...

It’s another piece of the transformation put in place by chief executive Emma Walmsley after taking over the helm of GSK two and a half years ago. 2020 is looking like an important year for the ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...